Back to Results

Nu Med Plus Inc (NUMD)

Nu Med Plus Inc. is a healthcare company focused on medical device development and commercialization. The company works on nitric oxide-based technologies, including a formulation that generates nitric oxide, a bedside delivery system for hospital use, a clinical unit designed for medical clinics and rehabilitation centers, and a mobile rechargeable device for delivering nitric oxide gas. Its portfolio also includes a nitric oxide system intended for research applications and a portable rechargeable device for inhaled nitric oxide delivery. Nu Med Plus was incorporated in 2011 and is based in Port Jefferson, New York. Its common stock is quoted on OTC Markets under the ticker NUMD.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
OTC-NUMD
$0.017
-6.5% Downside
Fair
—
—
—
Fair
—
—
—
0.0%
August 11, 2026
-29.5x
-5.4x
—
1.537 M
1.756 M
12.6%
55.0%
-2,006.8
—
104.3%
Valuation • Fair Value

Nu Med Plus Inc (OTC-NUMD) Fair Value by Valuation Model

Compare the primary fair value estimate for Nu Med Plus Inc (OTC-NUMD) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$0.017

Estimated downside of 6.5% versus the current market price.

Fair Value Confidence

Very low

Confidence level for the primary fair value estimate.

DCF Fair Value

NM

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$0.017

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use this section to compare the primary fair value estimate for Nu Med Plus Inc (OTC-NUMD) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Nu Med Plus Inc (OTC-NUMD)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

Not available

Data is currently unavailable.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

0 K

Current operating profitability reference.

EBITDA Forecast

Not available

Data is currently unavailable.

How to read profitability and growth

This section helps investors review Nu Med Plus Inc (OTC-NUMD) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Nu Med Plus Inc (OTC-NUMD)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

3

Weak quality score that deserves closer review.

Beneish M-Score

NM

Forensic accounting screen.

Altman Z-Score

-2,006.8

Lower score that deserves closer risk review.

FCF / Net Income

104.3%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Nu Med Plus Inc (OTC-NUMD). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Nu Med Plus Inc (OTC-NUMD)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 11, 2026

Days to Earnings

21

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Nu Med Plus Inc (OTC-NUMD), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Nu Med Plus Inc (OTC-NUMD) Stock Forecast & Technical Outlook

Review Nu Med Plus Inc (OTC-NUMD) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Nu Med Plus Inc (OTC-NUMD) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for Nu Med Plus Inc (OTC-NUMD) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Neutral

The daily technical read for Nu Med Plus Inc (OTC-NUMD) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Buy

The weekly technical read for Nu Med Plus Inc (OTC-NUMD) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Nu Med Plus Inc (OTC-NUMD) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Nu Med Plus Inc (OTC-NUMD)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Not available

Analyst recommendation data for Nu Med Plus Inc (OTC-NUMD) is not currently available.

Buy 0
Hold 0
Sell 0
FAQ • Fast Investor Answers

Nu Med Plus Inc (OTC-NUMD) Stock FAQ

Quick answers about Nu Med Plus Inc (OTC-NUMD) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$0.017
Estimated downside 6.5%
Valuation Rating
Overvalued
Estimated downside of 6.5%
Analyst Target
Not available
Data is currently unavailable
Financial Health
Fair
Current financial-health read

The current fair value estimate for Nu Med Plus Inc (OTC-NUMD) is $0.017. This implies an estimated downside of 6.5% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 6.5% versus the current market price.

An analyst price target for Nu Med Plus Inc (OTC-NUMD) is not currently available in the latest data file.

The current financial health read for Nu Med Plus Inc (OTC-NUMD) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Nu Med Plus Inc (OTC-NUMD) is August 11, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Nu Med Plus Inc (OTC-NUMD) is -29.5x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Nu Med Plus Inc is 1.537 M.

The current enterprise value listed for Nu Med Plus Inc is 1.756 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Nu Med Plus Inc is OTC-NUMD, and the stock is listed on OTC Markets.

Nu Med Plus Inc (OTC-NUMD) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for Nu Med Plus Inc is 12.6%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Nu Med Plus Inc is 55.0%. Free float helps investors understand how much of the share base is available for public trading.

Similar Healthcare Equipment & Supplies Stocks on OTC Markets View more

Essilor International SA (ESLOY) Essilor International SA (ESLOY)
Hoya Corp (HOCPY) Hoya Corp (HOCPY)
Siemens Healthineers AG ADR (SMMNY) Siemens Healthineers AG ADR (SMMNY)
Resmed Inc DRC (RSMDF) Resmed Inc DRC (RSMDF)
Terumo Corp ADR (TRUMY) Terumo Corp ADR (TRUMY)
Straumann Holding AG ADR (SAUHY) Straumann Holding AG ADR (SAUHY)
Sonova Holding AG (SONVY) Sonova Holding AG (SONVY)
Coloplast A (CLPBY) Coloplast A (CLPBY)
Fisher & Paykel Healthcare Ltd (FSPKF) Fisher & Paykel Healthcare Ltd (FSPKF)
Olympus Corp (OLYMY) Olympus Corp (OLYMY)
Demant A/S ADR (WILYY) Demant A/S ADR (WILYY)
Getinge Industrier AB (GNGBY) Getinge Industrier AB (GNGBY)
Sysmex Corp (SSMXY) Sysmex Corp (SSMXY)
ConvaTec Group plc ADR (CNVVY) ConvaTec Group plc ADR (CNVVY)
CochLear Ltd ADR (CHEOY) CochLear Ltd ADR (CHEOY)
Ansell Ltd ADR (ANSLY) Ansell Ltd ADR (ANSLY)
Carl Zeiss Meditec AG ADR (CZMWY) Carl Zeiss Meditec AG ADR (CZMWY)
Shandong Weigao Group Medical Polymer Co Ltd ADR (SHWGY) Shandong Weigao Group Medical Polymer Co Ltd ADR (SHWGY)
Elekta AB ADR (EKTAY) Elekta AB ADR (EKTAY)
Nihon Kohden Corp ADR (NHNKY) Nihon Kohden Corp ADR (NHNKY)
Top Glove Corporation Bhd ADR (TGLVY) Top Glove Corporation Bhd ADR (TGLVY)
Cyberdyne Inc ADR (CYBQY) Cyberdyne Inc ADR (CYBQY)
Paxman AB (PXMBF) Paxman AB (PXMBF)
Zomedica Corp (ZOMDF) Zomedica Corp (ZOMDF)